OCA
OLMA icon

Octagon Capital Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Octagon Capital Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-231,417
Closed -$2.17M – 30
2021
Q4 		$2.17M Buy
+231,417
New +$4.79M 0.42% 25

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Octagon Capital Advisors's OLMA Position: Q1 2022 in Review

Octagon Capital Advisors sold out of Olema Pharmaceuticals (OLMA) in Q1 2022, closing a stake of 231,417 shares — an estimated $2.17M sold.

Octagon Capital Advisors first reported a position in OLMA in Q4 2021 and held it in 1 quarter. The position peaked at $2.17M in Q4 2021. 91 funds tracked by Wall St. Rank hold OLMA as of Q1 2022.

  • Octagon Capital Advisors reported no remaining Olema Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 231,417 Olema Pharmaceuticals shares in Q1 2022, an estimated $2.17M.
  • Octagon Capital Advisors first reported a position in Olema Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Octagon Capital Advisors's Olema Pharmaceuticals position peaked at $2.17M in Q4 2021.
  • 91 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2022.

Based on Octagon Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.